SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 9/03/21 ReShape Lifesciences Inc. S-3 5:461K Toppan Merrill/FA |
Document/Exhibit Description Pages Size 1: S-3 Registration Statement - Securities for a HTML 225K Transaction 2: EX-5.1 Opinion of Counsel re: Legality HTML 20K 3: EX-23.1 Consent of Expert or Counsel HTML 6K 4: EX-23.2 Consent of Expert or Counsel HTML 6K 5: EX-23.3 Consent of Expert or Counsel HTML 5K
tm2126924-2_s3 - none - 4.9063097s |
|
Delaware
(State or other jurisdiction of
incorporation or organization) |
| |
26-1828101
(I.R.S. Employer
Identification No.) |
|
|
Large accelerated filer
☐
|
| |
Accelerated filer
☐
|
|
|
Non-accelerated filer
☒
|
| |
Smaller reporting company
☐
|
|
| | | |
Emerging growth company
☐
|
|
| | |||||||||||||||||||||
Title of each class of securities to be registered
|
| | |
Amount
to be registered |
| | |
Proposed
maximum aggregate offering price |
| | |
Amount of
registration fee |
| |||||||||
Common Stock
|
| | | |
|
(1)(2)
|
| | | | |
|
(1)(2)
|
| | | | | | | | |
Preferred Stock
|
| | | |
|
(1)(2)
|
| | | | |
|
(1)(2)
|
| | | | | | | | |
Depositary Shares
|
| | | |
|
(1)
|
| | | | |
|
(1)
|
| | | | | | | | |
Warrants
|
| | | |
|
(1)
|
| | | | |
|
(1)
|
| | | | | | | | |
Units
|
| | | |
|
(1)
|
| | | | |
|
(1)
|
| | | | | | | | |
Total
|
| | | | | | | | | | | $ | 150,000,000(3) | | | | | | $ | 16,365(4) | | |
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 3 | | | |
| | | | | 4 | | | |
| | | | | 6 | | | |
| | | | | 7 | | | |
| | | | | 8 | | | |
| | | | | 12 | | | |
| | | | | 15 | | | |
| | | | | 16 | | | |
| | | | | 16 | | | |
| | | | | 20 | | | |
| | | | | 21 | | | |
| | | | | 21 | | | |
| | | | | 21 | | | |
| | | | | 22 | | |
(in thousands, except per share amounts)
|
| |
Years Ended December 31,
|
| |||||||||
| | |
2019
|
| |||||||||
Net loss
|
| | | $ | (21,630) | | | | | $ | (74,207) | | |
Net loss per share – basic and diluted: | | | | | | | | | | | | | |
Net loss per share – basic and diluted
|
| | | $ | (3.12) | | | | | $ | (42.93) | | |
Shares used to compute basic and diluted net loss per share
|
| | | | 6,927,021 | | | | | | 1,728,722 | | |
| | |
Three Months Ended March 31,
|
| |||||||||
| | |
2020
|
| |||||||||
Net loss
|
| | | $ | (4,874) | | | | | $ | (4,311) | | |
Net loss per share – basic and diluted: | | | | | | | | | | | | | |
Net loss per share – basic and diluted
|
| | | $ | (0.70) | | | | | $ | (0.63) | | |
Shares used to compute basic and diluted net loss per share
|
| | | | 6,968,221 | | | | | | 6,859,240 | | |
| | | | | | ||||||||
Net loss
|
| | | $ | (3,604) | | | | | $ | (7,915) | | |
Net loss per share – basic and diluted: | | | | | | | | | | | | | |
Net loss per share – basic and diluted
|
| | | $ | (0.52) | | | | | $ | (1.15) | | |
Shares used to compute basic and diluted net loss per share
|
| | | | 6,911,497 | | | | | | 6,885,368 | | |
(in thousands, except per share amounts)
|
| |
Years Ended December 31,
|
| |||||||||
| | |
2019
|
| |||||||||
Net loss
|
| | | $ | (21,630) | | | | | $ | (74,207) | | |
Net loss per share – basic and diluted: | | | | | | | | | | | | | |
Net loss per share – basic and diluted
|
| | | $ | (5.54) | | | | | $ | (76.15) | | |
Shares used to compute basic and diluted net loss per share
|
| | | | 3,904,762 | | | | | | 974,481 | | |
| | |
Three Months Ended March 31,
|
| |||||||||
| | |
2020
|
| |||||||||
Net loss
|
| | | $ | (4,874) | | | | | $ | (4,311) | | |
Net loss per share – basic and diluted: | | | | | | | | | | | | | |
Net loss per share – basic and diluted
|
| | | $ | (1.24) | | | | | $ | (1.11) | | |
Shares used to compute basic and diluted net loss per share
|
| | | | 3,927,987 | | | | | | 3,866,554 | | |
| | | | | | ||||||||
Net loss
|
| | | $ | (3,604) | | | | | $ | (7,915) | | |
Net loss per share – basic and diluted: | | | | | | | | | | | | | |
Net loss per share – basic and diluted
|
| | | $ | (0.93) | | | | | $ | (2.04) | | |
Shares used to compute basic and diluted net loss per share
|
| | | | 3,896,011 | | | | | | 3,881,282 | | |
|
SEC registration fee
|
| | | $ | 16,365 | | |
|
Legal fees and expenses
|
| | |
|
(1)
|
| |
|
Printing expenses
|
| | |
|
(1)
|
| |
|
Accountants’ fees and expenses
|
| | |
|
(1)
|
| |
|
Transfer agent and registrar fees
|
| | |
|
(1)
|
| |
|
Trustee fees and expenses
|
| | |
|
(1)
|
| |
|
Depositary fees and expenses
|
| | |
|
(1)
|
| |
|
Warrant agent fees and expenses
|
| | |
|
(1)
|
| |
|
Miscellaneous expenses
|
| | |
|
(1)
|
| |
|
Total
|
| | | $ | (1) | | |
| | | | RESHAPE LIFESCIENCES INC. | |
| | | |
By:
/s/ Barton P. Bandy
Barton P. Bandy
President and Chief Executive Officer |
|
|
Signature
|
| |
Title
|
| |
Date
|
|
|
/s/ Barton P. Bandy
|
| |
President and Chief Executive Officer and Director
(principal executive officer) |
| | September 3, 2021 | |
|
|
| |
Chief Financial Officer
(principal financial and accounting officer) |
| | September 3, 2021 | |
|
|
| | Director | | | September 3, 2021 | |
|
/s/ Dan W. Gladney
|
| | Director | | | September 3, 2021 | |
|
/s/ Lori C. McDougal
|
| | Director | | | September 3, 2021 | |
|
|
| | Director | | | September 3, 2021 | |
This ‘S-3’ Filing | Date | Other Filings | ||
---|---|---|---|---|
Filed on: | 9/3/21 | S-3 | ||
9/1/21 | ||||
8/20/21 | 4 | |||
6/30/21 | 10-Q, SC 13D/A, SC 13G/A | |||
6/16/21 | 4 | |||
6/15/21 | 3, 8-K | |||
3/31/21 | 10-Q | |||
1/19/21 | 8-K | |||
12/31/20 | 10-K | |||
6/30/20 | 10-Q, 8-K | |||
12/31/19 | 10-K, 10-K/A | |||
List all Filings |